Mazen Albeldawi, Ashish Aggarwal, Surabhi Madhwal, Jacek Cywinski, Rocio Lopez, Bijan Eghtesad, Nizar N. Zein – 5 December 2011 – As survival after orthotopic liver transplantation (OLT) improves, cardiovascular (CV) disease has emerged as the leading cause of non–graft‐related deaths. The aims of our study were to determine the cumulative risk of CV events after OLT and to analyze predictive risk factors for those experiencing a CV event after OLT. We identified all adult patients who underwent OLT at our institution for end‐stage liver disease between October 1996 and July 2008.

Ashley N. Bedel, Trina S. Hemmelgarn, Rohit Kohli – 5 December 2011 – Cytomegalovirus (CMV) is the most common viral infection after solid organ transplantation (SOT). Safe and effective prophylactic regimens that decrease its incidence after SOT are essential for long‐term graft survival. Although valganciclovir is not Food and Drug Administration–approved for CMV prophylaxis in liver transplant recipients, postmarketing studies have shown valganciclovir to be as effective as ganciclovir in high‐risk adult patients undergoing SOT.

Shin Hwang, Tae‐Yong Ha, Chul‐Soo Ahn, Deok‐Bog Moon, Ki‐Hun Kim, Gi‐Won Song, Dong‐Hwan Jung, Gil‐Chun Park, Jung‐Man Namgoong, Sung‐Won Jung, Sam‐Youl Yoon, Kyu‐Bo Sung, Gi‐Young Ko, Byungchul Cho, Kyoung Won Kim, Sung‐Gyu Lee – 5 December 2011 – Because revascularization of the inferior right hepatic vein (IRHV) is a major component of right liver graft (RLG) reconstruction, we assessed the surgical techniques and clinical outcomes of IRHV reconstruction so that we could formulate practical guidelines for standardized procedures.

Lisa J. McGarry, Vivek S. Pawar, Hemangi R. Panchmatia, Jaime L. Rubin, Gary L. Davis, Zobair M. Younossi, James C. Capretta, Michael J. O'Grady, Milton C. Weinstein – 2 December 2011 – Recent research has identified high hepatitis C virus (HCV) prevalence among older U.S. residents who contracted HCV decades ago and may no longer be recognized as high risk. We assessed the cost‐effectiveness of screening 100% of U.S.

Lyna Zhang, Ajay Yesupriya, Dale J. Hu, Man‐huei Chang, Nicole F. Dowling, Renée M. Ned, Venkatachalam Udhayakumar, Mary Lou Lindegren, Yury Khudyakov – 2 December 2011 – Hepatitis A vaccination has dramatically reduced the incidence of hepatitis A virus (HAV) infection, but new infections continue to occur.

Rakesh Aggarwal, Shahid Jameel – 2 December 2011 – Hepatitis E refers to liver disease caused by the hepatitis E virus (HEV), a small, nonenveloped virus with a single‐stranded RNA genome. The virus has four genotypes, but only one serotype. Genotypes 1 and 2 exclusively infect humans, whereas genotypes 3 and 4 also infect pigs and several other mammalian species. Though HEV does not grow well in cell culture, several aspects of its biology and pathogenesis have been worked out using animal models and cell transfection studies, and by analogy with other related viruses.

Ainara Cano, Xabier Buqué, Maite Martínez‐Uña, Igor Aurrekoetxea, Ariane Menor, Juan L. García‐Rodríguez, Shelly C. Lu, M. Luz Martínez‐Chantar, José M. Mato, Begoña Ochoa, Patricia Aspichueta – 2 December 2011 – Very low‐density lipoprotein (VLDL) secretion provides a mechanism to export triglycerides (TG) from the liver to peripheral tissues, maintaining lipid homeostasis. In nonalcoholic fatty liver disease (NAFLD), VLDL secretion disturbances are unclear.

Antonio D'Avolio, Alessia Ciancio, Marco Siccardi, Lorena Baietto, Marco Simiele, Giuseppe Cariti, Andrea Calcagno, Antonina Smedile, Jessica Cusato, Stefano Bonora, Mario Rizzetto, Giovanni Di Perri – 2 December 2011

Simrat P.S. Saini, Bin Zhang, Yongdong Niu, Mengxi Jiang, Jie Gao, Yonggong Zhai, Jung Hoon Lee, Hirdesh Uppal, Hui Tian, Michael A. Tortorici, Samuel M. Poloyac, Wenxin Qin, Raman Venkataramanan, Wen Xie – 2 December 2011 – Overdose of acetaminophen (APAP), the active ingredient of Tylenol, is the leading cause of drug‐induced acute liver failure in the United States. As such, it is necessary to develop novel strategies to prevent or manage APAP toxicity. In this report, we reveal a novel function of the liver X receptor (LXR) in preventing APAP‐induced hepatotoxicity.

Jason Grebely, Gregory J. Dore – 2 December 2011